Bionano Genomics
BNGO
147 hedge funds and large institutions have $398M invested in Bionano Genomics in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 23 closing their positions.
108% more call options, than puts
Call options by funds: $38.3M | Put options by funds: $18.5M
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
3% less funds holding
Funds holding: 152 → 147 (-5)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
27% less capital invested
Capital invested by funds: $546M → $398M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$9.5M |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$7.48M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$7.24M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$3.08M |
| 5 |
Squarepoint
New York
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$17.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.18M |
| 3 |
Morgan Stanley
New York
|
-$5.69M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.61M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$2.92M |
BNGO Hedge Fund Activity: Q3 2021 in Review
147 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q3 2021, worth a combined $398M — down 27% from $546M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BNGO and 20 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 50 added.
The largest buyer was Northern Trust, adding an estimated $9.5M. The largest seller was Millennium Management, cutting an estimated $17.6M.
- 147 institutional investors held Bionano Genomics (BNGO) as of Q3 2021, down from 152 in Q2 2021.
- Funds reported $398M of Bionano Genomics stock for Q3 2021, down 27% quarter-over-quarter.
- 20 funds opened new Bionano Genomics positions in Q3 2021 and 23 closed out, a net change of -3 holders.
- The largest Bionano Genomics buyer in Q3 2021 was Northern Trust, an estimated $9.5M added.
- The largest Bionano Genomics seller in Q3 2021 was Millennium Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q3 2021.